Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
about
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Centipede venoms as a source of drug leads.Congenital Myasthenic Syndromes or Inherited Disorders of Neuromuscular Transmission: Recent Discoveries and Open Questions.New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease.Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.
P2860
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
@ast
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
@en
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
@nl
type
label
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
@ast
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
@en
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
@nl
prefLabel
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
@ast
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
@en
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
@nl
P2860
P1476
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
@en
P2093
Stephen D Meriney
Tyler B Tarr
P2860
P2888
P304
P356
10.1007/S12035-014-8887-2
P50
P577
2014-09-09T00:00:00Z
P6179
1003188252